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Abstract
Background: Acute pancreatitis is mostly caused by gallstones or sludge. Early decompression of the biliary tree by
endoscopic retrograde cholangiography (ERC) with sphincterotomy may improve outcome in these patients.
Whereas current guidelines recommend early ERC in patients with concomitant cholangitis, early ERC is not
recommended in patients with mild biliary pancreatitis. Evidence on the role of routine early ERC with endoscopic
sphincterotomy in patients without cholangitis but with biliary pancreatitis at high risk for complications is lacking.
We hypothesize that early ERC with sphincterotomy improves outcome in these patients.
Methods/Design: The APEC trial is a randomized controlled, parallel group, superiority multicenter trial. Within
24 hours after presentation to the emergency department, patients with biliary pancreatitis without cholangitis and
at high risk for complications, based on an Acute Physiology and Chronic Health Evaluation (APACHE-II) score of 8
or greater, Modified Glasgow score of 3 or greater, or serum C-reactive protein above 150 mg/L, will be
randomized. In 27 hospitals of the Dutch Pancreatitis Study Group, 232 patients will be allocated to early ERC with
sphincterotomy or to conservative treatment. The primary endpoint is a composite of major complications (that is,
organ failure, pancreatic necrosis, pneumonia, bacteremia, cholangitis, pancreatic endocrine, or exocrine
insufficiency) or death within 180 days after randomization. Secondary endpoints include ERC-related complications,
infected necrotizing pancreatitis, length of hospital stay and an economical evaluation.
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Discussion: The APEC trial investigates whether an early ERC with sphincterotomy reduces the composite endpoint
of major complications or death compared with conservative treatment in patients with biliary pancreatitis at high
risk of complications.
Trial registration: Current Controlled Trials ISRCTN97372133 (date registration: 17-12-2012)
Keywords: Acute pancreatitis, Treatment, Endoscopy, Pancreas, ERCP, ERC
Background
Acute pancreatitis is a leading cause for acute
hospitalization [1]. In most cases, pancreatitis results
from gallstones causing obstruction of Vater’s ampulla
[2, 3]. As biliary stones or sludge is thought to initi-
ate and aggravate pancreatitis, early biliary decompres-
sion – achieved by endoscopic retrograde cholangiography
(ERC) with sphincterotomy – may ameliorate the disease
course [4, 5]. In return, ERC with sphincterotomy itself
may also be associated with complications in up to 10 % of
patients [6, 7].
Several studies have investigated the effect of routine
ERC in biliary pancreatitis [8]. Guidelines state an undis-
puted indication for ERC in patients with concurrent
cholangitis and pancreatitis [2, 9]. In patients with mild
disease, early ERC is not indicated because in these
patients the risk for complications does not outweigh
the potential benefit [2, 9].
Recent guidelines advise to perform ERC with sphinc-
terotomy in case of pancreatitis with cholestasis, but
acknowledge the moderate quality of evidence for this
recommendation [2, 9]. For those patients with pancrea-
titis and at high risk for developing complications (that
is, predicted to be severe) without cholangitis, data are
conflicting. A meta-analysis found no beneficial effect of
routine early ERC compared with conservative treatment
[8]. However, the studies have notable shortcomings that
preclude reliable recommendations on the use of ERC in
patients with predicted severe biliary pancreatitis with-
out cholangitis [10]. First, patients included were those
with a low pre-likelihood of a biliary etiology, those at
low risk for developing complications (that is, predicted
to be mild), and those with cholangitis at presentation.
Second, patient selection criteria and study endpoints
(complications) varied considerably between studies and
also included clinically less relevant complications such
as pleural effusion or ascites. Third, the trials did not
present data separately regarding liver biochemical tests,
an omission that precludes performing a subgroup ana-
lysis for patients with cholestasis. Fourth, routine “early”
ERC was performed during a wide time frame (48 to
72 hours after admission), which may be too late to pre-
vent complications from severe disease or increase the
risk for ERC-related complications. Fifth, the trial proto-
cols did not specify precisely when the sphincterotomy
should be performed. This resulted in many patients
who underwent ERC without sphincterotomy. We
believe sphincterotomy should routinely be performed
during ERC to decompress the biliary duct, even in the
absence of gallstones or visible sludge in the common
bile duct [11–13]. Sixth, no criteria were set to guarantee
that ERCs were performed by experienced endoscopists,
although ERC is an intervention that requires consider-
able training and expertise [14, 15]. Finally, even if the
data of all the available randomized trials are pooled,
such analysis will still not have sufficient power to detect
clinically relevant and statistically significant effects of
early ERC with sphincterotomy on major complications or
death in patients with predicted severe biliary pancreatitis
without cholangitis [8, 16].
The APEC trial is designed to investigate whether early
ERC with sphincterotomy compared with conservative
treatment improves outcome in patients with biliary
pancreatitis without cholangitis who are at high risk for
complications.
Methods/Design
The APEC trial is a randomized controlled, parallel
group, superiority, multicenter trial. Patients with acute
pancreatitis will be assessed for study eligibility within
24 hours after presentation to the emergency depart-
ment. Patients with biliary pancreatitis without cholan-
gitis and at high risk of developing severe disease are
eligible for randomization. Patients are randomized to
early ERC with sphincterotomy or to conservative treat-
ment (see Additional file 1: Figure S1 and Additional
file 2: Figure S2). Blinding of the patients and physi-
cians for either treatment (ERC or conservative treat-
ment) is unfeasible. The trial will be conducted in 27
hospitals of the Dutch Pancreatitis Study Group. The
APEC trial protocol is in accordance with the Spirit
Guidelines [17].
Primary endpoint
The primary endpoint is a composite of major com-
plications or death occurring within 180 days after
randomization (that is, the composite endpoint can
only occur once per patient). Major complications
are defined as persistent organ failure, pancreatic ne-
crosis, bacteremia, cholangitis, pneumonia, and
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pancreatic endocrine or exocrine insufficiency (see
Additional file 3: Table S1 for definitions).
Secondary endpoints
The secondary endpoints are as follows:
1. “Per protocol” analysis of the primary endpoint
2. “As treated” analysis of the primary endpoint
3. Individual components of the primary end point
4. Multivariable analysis of the primary endpoint in
case of significant differences in baseline variables
5. Infected necrotizing pancreatitis
6. Need for new intensive care unit admission
7. Length of stay at intensive care unit
8. ERC-related complications (see Additional file 4:
Table S2 for definitions [39-41] )
9. Cholangitis during admission
10. Number of endoscopic, radiological, and operative
(re-)interventions
11. Readmission for biliary events (recurrent acute
biliary pancreatitis, cholecystitis, biliary colics, or
cholangitis)
12. Difficulty of cholecystectomy (as scored by Visual
Analog Scale 1 to 10)
13. Quality of life (Short Form-36 and EQ5D-5 L)
including quality adjusted life years (QALY)
14. Direct medical costs and direct and indirect
nonmedical costs
Inclusion criteria
Inclusion criteria are as follows:
1. Acute pancreatitis, which is defined as the presence
of at least two out of the following three criteria: 1)
pain in the upper abdomen, 2) serum amylase or
lipase concentration > 3 times the upper limit of
normal, or 3) imaging features of acute pancreatitis
on computed tomography (CT) or magnetic
resonance imaging (MRI) [18].
2. High risk of developing severe disease (that is,
predicted to be severe) based on either one of the
following criteria: Acute Physiology and Chronic
Health Evaluation (APACHE II score) ≥ 8 [19] (see
Additional file 5: Table S4), 2) Modified Glasgow
score ≥ 3 [20] (see Additional file 6: Table S3), or 3)
C-reactive protein > 150 mg/L [21, 22].
3. High probability of a biliary etiology based on at least
one of the following criteria: 1) gallstones or biliary
sludge on imaging (any type), 2) dilated common
bile duct on imaging defined as > 8 mm in
patients ≤ 75 years or > 10 mm in patients > 75 years,
3) alanine aminotransferase (ALAT) > two times the
upper limit of normal (no absolute numerical value is
chosen because of the multicentric design with
varying upper limits among hospitals and sex-based dif-
ferences in the upper limit of normal values [23–25]).
4. Ability to perform ERC within 24 hours after
presentation to the emergency department and no
more than 72 hours after symptom onset.
5. In case of a previous episode of necrotizing
pancreatitis, patient should be fully recovered
(confirmed on imaging).
6. Age ≥18 years.
7. Written informed consent.
Exclusion criteria
The exclusion criteria include the following:
1. Cholangitis (see Additional file 3: Table S1 for
definition).
2. Pancreatitis due to other causes such as alcohol
abuse (more than 4 units per day), metabolic causes
(hypertriglyceridemia or hypercalcemia), medication,
trauma, etc.
3. Previous pancreatic sphincterotomy or needle knife
precut.
4. Chronic pancreatitis (see Additional file 7: Table S5
for definition).
5. International Normalized Ratio that cannot be
corrected to less than 1.5 with clotting factors or
fresh frozen plasma.
6. Pregnancy.
Randomization
Patients are randomized to early ERC with sphincterot-
omy or to conservative treatment (1:1 ratio) with a web-
based randomization module (ALEA, Academic Medical
Center, Amsterdam, The Netherlands) in random blocks
of two, four or six. At randomization, patients are strati-
fied according to the presence of cholestasis and for
region of the hospital. Cholestasis is defined as a serum
bilirubin > 40 μmol/L at randomization or a dilated com-
mon bile duct (defined as > 8 mm in patients ≤ 75 years
or > 10 mm in patients > 75 years).
Treatment protocol
Early ERC with sphincterotomy
Early ERC with sphincterotomy is performed within
72 hours after symptom onset and within 24 hours of
hospital admission. A sphincterotomy is always performed
irrespective of the presence of the common bile duct
stones. ERC is performed by or under the direct supervi-
sion of an experienced endoscopist, which defined as a
person who has done more than 400 ERCs in his or her
lifetime and has performed more than 50 ERCs yearly on
average in the previous 3 years. When unable to cannulate
the common bile duct, even after precut sphincterotomy,
the ERC procedure will be ended, and the patient will be
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treated conservatively. After the patient has recovered
from the acute pancreatitis attack, a repeat ERC is sched-
uled to perform a full sphincterotomy. According to the
intention-to-treat principle, these patients will be analyzed
according to their original treatment allocation, that is,
early ERC with sphincterotomy. In the case of incomplete
stone extraction, a plastic endoprosthesis is inserted, and
an elective ERC is scheduled. Antibiotics are only admin-
istered in case of contrast injection without adequate
biliary drainage.
Conservative treatment
Patients in the conservative group are managed accord-
ing to the conservative supportive treatment regimen for
patients with acute biliary pancreatitis as described in
the paragraph below. A rescue ERC is performed when a
patient develops cholangitis (see Additional file 3:
Table S1 for definition). Whenever the attending phys-
ician is in doubt concerning whether or not an ERC
should be performed, the study coordinator presents
the case to an expert panel. This expert panel, consist-
ing of an independent gastroenterologist and a gastro-
intestinal surgeon, provides a treatment advice within
24 hours. Retained bile duct stones are removed
during an elective ERC when the patient is recovered
from the initial pancreatitis episode.
General treatment regimen
Both groups are treated with intravenous infusion of
fluids to ensure adequate hydration and diuresis, appro-
priate analgesic treatment, enteral nutrition if necessary,
treatment of endocrine and exocrine pancreatic insuffi-
ciency, and a gastric tube in case of vomiting. No anti-
biotic prophylaxis is given. The treating physician
assesses whether the patient requires intensive care
monitoring or further supportive measures (for example,
mechanical ventilation). All patients will undergo a
contrast-enhanced CT (CECT) 5 to 7 days after hospital
admission for an assessment of pancreatic necrosis. If a
patient recovers quickly and is discharged within 5 days,
a routine CECT will not be performed, and the disease
will be considered mild. Readmission within 10 days
after the initial discharge for complications related to
pancreatitis is regarded as a primary admission. The tim-
ing of the cholecystectomy is determined by the treating
physician depending on the patient’s condition and out-
come of the pancreatitis.
Data collection
Clinical data are collected using case record forms. At
all sites, an independent monitor, unblinded to the
treatment allocation, will assess the study forms, includ-
ing the informed consent documents, and compare these
with source documents. The in-hospital utilization of
healthcare will be registered as part of the data collection.
Out-of-hospital use of healthcare will be documented by
self-administered questionnaires.
Follow-up
After hospital discharge, patients are seen at the out-
patient clinic and further monitored at the discretion of
the physician. After 1, 3, and 6 months, patients will
receive a questionnaire (SF-36, SF-HLQ, and EQ5D-5 L,
respectively) [26, 27]. A visit is scheduled at 3 months
after randomization to identify persistent common bile
duct stones or to detect endocrine or exocrine pancre-
atic insufficiency (serum liver and glucose measurements
and fecal elastase).
Safety
An independent Data Safety Monitoring Committee
(DSMC) has been appointed to assess protocol adher-
ence, patient recruitment, and patient safety. All physi-
cians who are involved in the trial are asked to report all
adverse events to the coordinating investigator. Adverse
events are reported using the online module (https://
www.toetsingonline.nl) of the Dutch Central Committee
on Research involving human subjects. All adverse
events are collected and reported unblinded to the
DSMC every time 60 patients are randomized, after
randomization of the final patient, and at the end of
follow-up of the final patient. In addition, a continuous
sequential safety analysis on mortality is performed to
ensure the patient’s safety throughout the trial. The
DSMC discusses all adverse events and the progress of
the trial and reports to the trial steering committee. A
copy is sent to the ethical committee and all physicians
who are involved with the study.
Ethics
The APEC trial is performed in accordance with the
declaration of Helsinki and the Dutch law regarding
research involving human subjects (Wet Medisch
wetenschappelijk Onderzoek met Mensen). Informed
consent will be obtained from each participant. The
ethical committee of the Erasmus Medical Center in
Rotterdam, the Netherlands, approved the study protocol
on the 12th of December 2012. Subsequently, the boards
of the 27 participating hospitals gave permission for
conducting the trial (see Additional file 8 Ethical bodies
that approved the trial). The APEC trial is registered with
identification number ISRCTN97372133.
Statistical considerations
Sample size calculation
The sample size calculation is based on a recent Dutch
multicenter observational study of patients with biliary
pancreatitis at high risk for complications [11]. The
Schepers et al. Trials  (2016) 17:5 Page 4 of 9
primary endpoint occurred in 32 % of the patients in
which ERC was performed compared with 46 % of the
patients who were treated conservatively. Taking into
account that ERC was not always performed within
24 hours and that sphincterotomy was not routinely
performed, a correction factor of 2 % for both percent-
ages is added to both incidence rates. The APEC trial is
a superiority trial in which the sample size calculation is
based on the assumption that early ERC with sphincter-
otomy reduces the incidence of the primary endpoint by
18 % (48 % to 30 %). With a power of 80 %, a two-sided
significance level of 5 % and a 1 % drop-out rate, a total
of 232 patients are required to be included in the study
(http://www.stat.ubc.ca/~rollin/stats/ssize/b2.html,
accessed 20 July 2015)).
Descriptive statistics
The following patient characteristics before randomization
will be described: age, sex, body mass index, comorbidity,
American Society of Anesthesiologists (ASA) score, dur-
ation of symptoms before randomization, duration of
symptoms before ERC, serum bilirubin levels, dilated
common bile duct on ultrasound or computed tomog-
raphy, presence of (multi) organ failure or systemic in-
flammatory response syndrome (SIRS), Sequential Organ
Failure Assessment (SOFA) scale [28], Multiple Organ
Dysfunction Score (MODS) [29], predicted disease sever-
ity according to APACHE-II, modified Glasgow, blood
urea nitrogen, and C-reactive protein. Data will be pre-
sented in percentages for categorical variables. Continuous
data with a normal distribution will be presented as a
mean with standard deviation and as median with inter-
quartile range in case of skewed distribution.
Analyses
After 232 patients have completed their 6 months of
follow-up, raw data regarding potential endpoints will be
presented to an adjudication committee blinded to the
treatment allocation to determine whether the endpoints
meet the protocol-specified criteria. The study coordin-
ator will blind the patient reports for treatment alloca-
tion. Each member of the committee will individually
assess the potential endpoints. In case of dissenting
opinions, a consensus meeting will follow. Only after
consensus has been reached on each individual endpoint
for each individual patient will a final analysis be
performed by an independent statistician, unblinded for
treatment allocation. Primary analysis, using the Pear-
son’s Chi-squared test, is based on the intention-to-treat
principle, with patients being analyzed according to
original treatment allocation, regardless of whether the
cannulation or sphincterotomy was successful. For
exploratory reasons a per-protocol analysis will be per-
formed to compare treatment groups. A tabular listing
of all patients excluded from the intention-to-treat
populations will be provided together with the reasons
for exclusion. Data will be presented as relative risks
with 95 % confidence intervals. A two-tailed P < 0.05 is
considered statistically significant.
Additional analyses
Predefined subgroup analysis will be done according to
the presence of cholestasis. Logistic regression models
will be used to test whether treatment effects differ
significantly between these subgroups. Secondary end-
points will be compared using the Pearson’s chi-squared
test or Mann-Whitney U test. Additionally, secondary
endpoints will be analyzed separately using Cox regres-
sion analysis censoring patients no longer at risk and
categorizing missing data as no event. For all other
analyses, data will be considered missing at random. To
evaluate differences in systemic inflammatory response
after randomization, the APACHE-II, C-reactive protein
levels, and presence of SIRS from randomization to day
7 will be calculated and compared between the treat-
ment groups. To gain further insight into factors that
are predictive of major complications or death after
ERC, an exploratory analysis of the effects of (essential)
baseline covariates (and potential interactions) will be
performed using logistic regression analysis. The essential
baseline covariates that will be studied are demographics,
comorbidity, predicted severity prior to randomization,
presence of organ failure prior to randomization, cholesta-
sis, and duration of symptoms prior to randomization. In
addition, the time between the start of symptoms and the
ERC will be studied.
Direct medical and nonmedical costs and indirect
costs will be compared to assess costs per patient with
poor outcome (death or severe complications). Validated
questionnaires will be analyzed to assess differences in
the quality of life and provide input to compare costs
per quality-adjusted life year (QALY). Health utility
scoring algorithms for the EQ5D-5 L health status
profiles available from the literature, based on prefer-
ences in the general population using time trade-off
elicitation techniques, will be used to derive a QALY
estimate for each patient. This QALY will be calculated
as the product sum of health utilities and the lengths of the
periods between the successive measurements [30, 31].
Premature termination of the study
An interim-analysis will be performed when 116 patients
(50 %) have been randomized and discharged after their
initial hospital admission. Raw data pertaining to poten-
tial endpoints will be presented to an adjudication
committee blinded for treatment allocation to determine
whether the endpoints meet the protocol-specified
criteria. In case of dissenting opinions, a consensus
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meeting will follow. The interim-analysis will be
performed by an independent statistician who re-
ports to the DSMC. The DSMC will have unblinded
access to all data when discussing the results of the
interim-analysis and when reporting to the steering
committee. The steering committee will decide upon
continuation of the APEC trial. The Haybittle-Peto
approach is used for beneficial effect, meaning that
the trial will be ended using symmetric stopping
boundaries at P < 0.001 [32, 33]. The trial will not be
stopped for futility.
Discussion
The APEC trial is designed to provide an answer to a
persisting clinical dilemma: whether or not to routinely
perform early ERC with sphincterotomy in patients with
biliary pancreatitis at high risk for complications but
without concurrent cholangitis. Guidelines clearly advise
urgent ERC with sphincterotomy in patients with
concomitant cholangitis and discard this intervention in
patients with a predicted mild disease course. A recent
Cochrane meta-analysis comparing routine ERC versus
conservative treatment found no difference in complica-
tions and death in patients with pancreatitis at high risk
for complications [8]. However, besides some notable
limitations in the design of the studies included, the
pooled sample size of patients with biliary pancreatitis
who were at high risk for complications without concur-
rent cholangitis was too small to detect a difference in
effect. As long as the precise role remains unclear of
early ERC in biliary pancreatitis in patients at high risk
for complications without concurrent cholangitis, either
a potentially beneficial intervention is withheld from
patients or they are exposed to a treatment from which
they cannot benefit and may only suffer its potential
complications. The APEC trial is the first randomized
controlled trial in this particular subset of patients that
is adequately powered to detect statistically significant
differences in clinically relevant outcomes of early ERC
and sphincterotomy. The APEC trial will also provide in-
sights into the cost-effectiveness of routine early ERC
and sphincterotomy and the amount of cost savings that
can be achieved.
To date, the optimal timing of early ERC in biliary
pancreatitis is unclear. Previous studies suggest that
the severity of the pancreatitis is related to the dur-
ation of biliopancreatic ductal obstruction [34, 35].
These observations provide the rationale to perform
an ERC and sphincterotomy early after the onset of
symptoms. For this reason, albeit logistically challen-
ging, in the APEC trial, ERC with sphincterotomy is
performed within 72 hours after symptom onset and
within 24 hours after hospital admission to achieve
the optimal effect of the intervention.
Recent guidelines state that early ERC is probably
beneficial in patients with cholestasis [2], albeit with the
acknowledgement that the level of evidence is low to
moderate. To investigate whether the potential beneficial
effects of ERC with sphincterotomy depend on the pres-
ence of cholestasis, patients in the APEC trial will be
stratified according to this baseline variable.
The primary endpoint of the APEC trial is a composite
of major complications and death. One of the major
complications that may occur in the course of biliary
pancreatitis is pancreatic necrosis. In contrast to the
definition of necrotizing pancreatitis according to the
recently updated Atlanta classification, we excluded extra-
pancreatic necrosis alone as a major complication [18]
with the rationale that extrapancreatic necrosis alone is
suggested to be a separate entity in necrotizing pancrea-
titis and is associated with fewer complications compared
with pancreatic necrosis [36].
Commonly used biochemical and radiologic predictors
of biliary obstruction are unreliable in the early phase of
acute pancreatitis [37]. Advanced imaging modalities
such as magnetic resonance cholangiopancreatography
(MRCP) and endoscopic ultrasound (EUS) have im-
proved accuracy in detecting common bile duct stones
and could therefore be applied to select patients for
therapeutic ERC [38]. However, EUS is not available in
all centers. Moreover, performing either MRCP or EUS
within 24 hours after presentation can be challenging
and may prove to be unfeasible because of limited local
resources and expertise, particularly during on-call
hours. The use of MRCP and EUS before ERC is also
not incorporated in the APEC-trial because it is hypoth-
esized that the beneficial effect of an early sphincterot-
omy might also be present irrespective of a stone or
visible sludge in the CBD [11]. Hence, even if CBD
stones are detected by EUS or MRCP, the question
remains whether sphincterotomy in the early phase of
the disease improves outcome in these patients.
The APEC trial will be performed in 27 centers that
participate in the Dutch Pancreatitis Study Group. The
fact that ERCs will not be performed exclusively in high
volume expert centers but in hospitals nationwide by
endoscopists with a predefined skill level ensures that
the results of the APEC trial can be extrapolated to
comparable clinical practice settings worldwide.
Conclusion
In conclusion, the APEC trial is a multicenter ran-
domized trial that investigates whether routine early
ERC with sphincterotomy reduces the composite
endpoint of major complications or death in patients
with biliary pancreatitis at high risk for comp-
lications, but without cholangitis, as compared with
conservative treatment.
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Trial status
The trial was registered on the 7th of December 2012 in
the ISRCTN register. The first patient was randomized
on the 1st of March 2013. To date, 144 patients have
been randomized and inclusion is on schedule.
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